Search

Displaying results 911 - 920 of 5895 in total
  1. Drug

    Epinephrine

    go.drugbank.com/drugs/DB00668
    ApprovedInvestigationalVet approved

    On August 16, 2018, Teva Pharmaceuticals USA gained approval to market its generic epinephrine auto-injector in 0.3 mg and 0.15 mg strengths [L4353]. … to drugs, animal serums and other allergens, and to prolong the action of infiltration anesthetics [F2136].

    Mixtures: Xylocaine 2% W Epinephrine 1:100000, Xylocaine 2% W Epinephrine 1:200000Products: Gingi Pak Cord No 1, Gingi-pak Max Z-twist No 1
  2. Drug

    Belumosudil

    go.drugbank.com/drugs/DB16703
    ApprovedInvestigational

    [A236644,L34759] Belumosudil was first approved by the FDA in July 2021, under the brand name Rezurock, for the treatment of chronic GVHD in patients who have tried and failed at least two prior lines … [L34749] In the treatment of GVHD, a condition in which donor T-cells begin to attack recipient tissues following allogeneic hematopoeitic stem cell transplantation (HSCT), belumosudil helps to resolve

  3. Drug

    Andexanet alfa

    go.drugbank.com/drugs/DB14562
    Approved

    to thrombin [A35558]. … Andexanet alfa is currently under regulatory review by the European Union and is undergoing clinical development in Japan [A35518].

  4. Drug

    Talquetamab

    go.drugbank.com/drugs/DB16678
    ApprovedInvestigational

    It works to recruit CD3-expressing T cells to GPRC5D-expressing multiple myeloma cells to induce T-cell–mediated cytotoxicity. … It consists of two arms - anti-GPRC5D and anti-CD3 arms - linked by two interchain disulfide bonds, each arm comprising a heavy and light chain.

  5. Drug

    Ergoloid mesylate

    go.drugbank.com/drugs/DB01049
    Approved

    [L2640] To know more about the individual components of the ergoloid mixture, please visit [DB11275], [DB11274], [DB11273] and [DB13345]. … [T90] The derivatives of this fungus are identified to be about 350 different substances from which the components of the ergoloid mesylate mixture are composed of the dihydrogenated ergot alkaloid derivatives

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeSynonyms: co-dergocrine mesilate, co-dergocrine mesylate
  6. Drug

    Vardenafil

    go.drugbank.com/drugs/DB00862
    Approved

    Compared to [sildenafil] and [tadalafil], vardenafil is a more potent inhibitor of PDE5; however, its selectivity for other PDE isoforms is lower than the one detected for tadalafil. … Although other PDE5 inhibitors such as [sildenafil] and [tadalafil] have been associated with rare cases of acute liver injury, the use of vardenafil has not been linked to hepatotoxic effects.

    Products: VARDENAFIL TEVA GENERICS
  7. Drug

    Vorinostat

    go.drugbank.com/drugs/DB02546
    ApprovedInvestigational

    A recent study suggested that vorinostat also possesses some activity against recurrent glioblastoma multiforme, resulting in a median overall survival of 5.7 months (compared to 4 - 4.4 months in earlier … Vorinostat (rINN) or suberoylanilide hydroxamic acid (SAHA), is a drug currently under investigation for the treatment of cutaneous T cell lymphoma (CTCL), a type of skin cancer, to be used when the disease

  8. Drug

    Peginesatide

    go.drugbank.com/drugs/DB08894
    ApprovedWithdrawn

    Chemically, peginesatide is designed to mimic the pharmacological activity of erythropoietin, but is not a replica of the structure itself. … Peginesatide consists of two 21-amino acid chains that are covalently bonded by a linker derived from iminodiacetic acid and β-alanine. FDA approved March 27, 2012.

  9. Drug

    Methyldopa

    go.drugbank.com/drugs/DB00968
    ApprovedInvestigational

    [L32619] Methyldopa is also available as intravenous injection, which is used to manage hypertension when oral therapy is unfeasible and to treat hypertensive crisis.[L32624] … Methyldopa works by binding to alpha(α)-2 adrenergic receptors as an agonist, leading to the inhibition of adrenergic neuronal outflow and reduction of vasoconstrictor adrenergic signals.

  10. Drug

    Dupilumab

    go.drugbank.com/drugs/DB12159
    ApprovedInvestigational

    Dupilumab is a fully human monoclonal antibody of the immunoglobulin G4 subclass that binds to the interleukin-4 (IL-4) receptor, inhibiting the receptor signaling pathways. … It is currently used to treat atopic dermatitis, asthma as an add-on maintenance treatment, chronic rhinosinusitis with nasal polyposis, and eosinophilic esophagitis.